Trikafta access in Pakistan: the DRAP Personal Use Import pathway

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Trikafta is the Vertex Pharmaceuticals triple-combination CFTR modulator approved by the US FDA in October 2019 for cystic fibrosis patients aged 2 years and older who carry at least one F508del mutation in the CFTR gene. Cystic fibrosis is less common in Pakistan than in European or North American populations, but it is not absent: pediatric pulmonology services at Aga Khan University Hospital in Karachi and at the Children's Hospital and Institute of Child Health in Lahore see CF cases through their referral networks, and a small but identifiable cohort of Pakistani children and adolescents carries an F508del allele. The Drug Regulatory Authority of Pakistan (DRAP) does not register Trikafta for routine local distribution, so families that need the medicine work through DRAP's Special Permission framework, also known as the Personal Use Import NOC, filed on DRAP's Online Import and Export System.

Reserved for you.

Why Pakistani families reach for Trikafta through NPP

Three patterns of access gap operate in Pakistan's specialty drug market: registered but not stocked, registered for a different indication, and not registered locally at all. Trikafta sits in the third category. Vertex has not filed for routine DRAP registration of Trikafta or Kaftrio in Pakistan, which is consistent with Vertex's commercial pattern in middle-income markets where the CF population is small relative to registration cost. For a Pakistani family with a pediatric or adolescent CF patient on a documented F508del genotype, the lawful route to FDA-approved Vertex-manufactured Trikafta is the DRAP Special Permission pathway, not a parallel-import or gray-market channel.

The drug itself supports the named-patient case. Roughly 90 percent of people with cystic fibrosis worldwide carry at least one F508del allele, and that is the eligibility gate for Trikafta. The FDA expanded the label to ages 6 and older in June 2021 and to ages 2 and older in April 2023, which broadens the Pakistani pediatric population eligible for the drug. Pakistani families managing CF chronically cannot tolerate weeks-long gaps in CFTR-modulator therapy, and the documented chain-of-custody route through DRAP is the only sustainable answer for ongoing supply.

The DRAP Personal Use Import pathway for Trikafta

DRAP regulates the import of medicines through the Quality Assurance and Laboratory Testing (QA&LT) Division's Import and Export Section, with Drug Registration Board oversight for new product registration matters. For an FDA-approved specialty medicine that is not registered in Pakistan, the agency issues a Special Permission (also called the Personal Use Import NOC). Applications are filed through DRAP's Online Import and Export System (OIES). For a tertiary-hospital case, the institutional pharmacy files the application directly; for a smaller-hospital or private-practice case, a DRAP-licensed specialty importer based in Karachi or Lahore files on behalf of the patient.

For Trikafta the clinical-justification angle is genotype-specific. A complete application typically includes:

• A clinical justification letter from the treating pediatric or adult pulmonologist naming the patient's CFTR genotype (at least one F508del mutation, or another responsive variant on the current FDA label), confirmed by a written CFTR genetic-testing report from a recognised laboratory
• The treating physician's Pakistan Medical and Dental Council (PMDC) license verification, with specialist registration (FCPS Pakistan pediatric pulmonology, FCPS adult pulmonology, or equivalent foreign qualification) where applicable
• The patient identifier: CNIC for an adult patient, B-Form for a minor (which is the standard pediatric case for Trikafta in Pakistan)
• Product details: Trikafta, the specific strength (adult tablet for patients aged 12 and older or pediatric patients 25 kg and above; lower-strength tablet for patients 6 to 11 under 25 kg; granule packets for patients ages 2 to 5 in two weight bands at 10 kg and 14 kg thresholds), manufacturer Vertex Pharmaceuticals, country of origin, pack size, and requested quantity
• The destination dispensing facility's hospital pharmacy license, confirming that the receiving pharmacy is licensed to dispense imported pharmaceuticals
• A manufacturer or authorised distributor letter confirming the product is genuine and was sourced through the legitimate US specialty-pharmacy chain
• A chain-of-custody plan from the US source through international air freight to Karachi, Lahore, or Islamabad and on to the dispensing pharmacy

Routine personal-use cases typically clear in four to eight weeks from a complete submission. Complex cases involving non-F508del responsive variants, recently expanded label indications, or first-time imports through a smaller importer can extend to ten to sixteen weeks. Reserve Meds plans on the longer end of the routine range and treats any faster turnaround as upside. Trikafta is room-temperature stable, which removes cold-chain pressure on the customs window but does not change the underlying DRAP timeline.

Where Trikafta gets dispensed in Pakistan

Trikafta is an oral therapy. There is no infusion-centre requirement, and the dispensing footprint is wider than for cold-chain biologics. The institutions that handle named-patient imports as an established workflow are concentrated in Karachi, Lahore, and Islamabad. For pediatric CF cases the natural homes are the pediatric pulmonology services at Aga Khan University Hospital (AKUH) in Karachi, the pediatric programs at Indus Hospital and Health Network in Karachi, the pediatric specialty services at Liaquat National Hospital in Karachi, the Children's Hospital and Institute of Child Health in Lahore, the pediatric services at Shaukat Khanum Memorial Cancer Hospital and Research Centre in Lahore for families already in the Shaukat referral network, the pediatric programs in the Combined Military Hospitals (CMH) network, and Shifa International Hospital in Islamabad for federal-capital-region families.

Adult CF cases route through adult pulmonology services at AKUH, Liaquat National, PKLI, CMH Rawalpindi or CMH Lahore, and Shifa International. Families in Peshawar, Quetta, Multan, Faisalabad, or smaller cities typically travel to a major-city facility for treatment initiation and then continue chronic dispensing through the same institutional pharmacy or a partner importer. Reserve Meds plans logistics to a major-city dispensing facility and coordinates with the family on the in-country last-mile.

Real cost picture for Trikafta in Pakistan

US wholesale acquisition cost for Trikafta is approximately USD 322,000 per patient per year, which works out to roughly USD 26,800 per month for adult-strength dosing. The Pakistani rupee has been volatile across the last several years; as of May 2026 the USD to PKR rate sits in the 278 to 280 range, with Pakistan's annual CPI inflation running at 10.9 percent in April 2026 (well above the State Bank of Pakistan's 5 to 7 percent target). For planning purposes a USD 26,800 monthly drug acquisition translates to roughly PKR 7.5 million at current exchange rates, and the rupee figure can move materially over a single quote-to-shipment cycle.

Because PKR has been volatile historically and inflation is again rising, Reserve Meds quotes in USD and accepts wire transfers from any USD-accessible source. International logistics for Trikafta runs at the lower end of the Reserve Meds lane range, typically USD 400 to USD 800, because the product is ambient-controlled rather than cold-chain. DRAP fees and FBR Customs charges are nominal relative to the drug itself. The Reserve Meds coordination fee is itemised separately on every firm quote. On insurance, Adamjee, Jubilee, EFU, State Life, IGI, and Pak-Qatar each assess named-patient imports case by case. Most Pakistani health plans do not reimburse imported, unregistered specialty drugs; some pay a partial percentage on a case-by-case basis. The realistic default is cash-pay. We supply the documentation that lets a family file a claim if they want to try; we do not promise insurer outcomes.

Typical timeline for Trikafta in Pakistan

For a pediatric or adolescent CF patient with a clean F508del genotype letter, current weight-band confirmation, and a CF-experienced pediatric pulmonologist at AKUH, Indus, Children's Hospital Lahore, or another major center, the typical end-to-end cycle is 6 to 10 weeks. The DRAP Special Permission step generally runs 4 to 8 weeks for routine cases on the OIES portal. US-side sourcing and release through the Vertex specialty-pharmacy network adds approximately 1 to 2 weeks. International ambient-controlled air freight and FBR Customs clearance at Karachi, Lahore, or Islamabad airport are typically 3 to 7 days. Complex cases with non-F508del responsive variants or first-time imports through a smaller importer can extend the front-end DRAP step to 10 to 16 weeks. Timelines are presented as typical ranges, not promises; specific dates are confirmed at firm-quote issuance.

What your physician needs to provide

The clinical justification letter for Trikafta is the centrepiece of the DRAP package. For this product the letter typically includes:

• The patient's confirmed cystic fibrosis diagnosis with ICD-10 coding and CFTR genotype documented on a genetic-testing report (at least one F508del allele, or another responsive variant on the current FDA label)
• The patient's current age and weight, with the weight band that determines the appropriate Trikafta strength (adult strength for patients aged 12 and older or pediatric patients 25 kg and above; lower-strength tablet for patients 6 to 11 under 25 kg; granule packets for patients ages 2 to 5 in two weight bands at 10 kg and 14 kg thresholds)
• Prior CF treatment history including any prior CFTR-modulator exposure (Kalydeco, Orkambi, Symdeko, or Trikafta itself) and current clinical status (FEV1 if measurable, weight trajectory, pulmonary exacerbation frequency)
• Justification for why no locally registered alternative is suitable; for Trikafta in Pakistan the underlying fact is that the drug is not DRAP-registered for routine distribution, so any access requires the Special Permission route
• The dosing plan: morning tablet plus evening tablet 12 hours apart, both with fat-containing food required for adequate ivacaftor absorption
• The monitoring plan: baseline and periodic liver function tests (ALT, AST, bilirubin) every three months for the first year then annually, baseline and follow-up ophthalmologic examination in pediatric patients for cataracts, and medication reconciliation for CYP3A interactions (rifampin and St John's wort contraindicated; strong inhibitors require dose reduction to twice-weekly)
• The pharmacovigilance commitment to report adverse events through the DRAP Pharmacovigilance Centre as part of the post-import obligation

PMDC-licensed pediatric pulmonologists and adult pulmonologists at AKUH, Indus, Liaquat National, Children's Hospital Lahore, Shaukat Khanum, PKLI, the CMH network, and Shifa International all hold full signing authority on Special Permission applications.

Common questions about Trikafta in Pakistan

Will Adamjee, Jubilee, EFU, or State Life cover Trikafta? Coverage for named-patient imports of unregistered drugs is uncommon across Pakistani health plans. Some plans pay a partial percentage on a case-by-case basis. We supply the documentation set the insurer needs to assess the claim; the claim itself is yours or your hospital's to file. The realistic default is cash-pay.

How does Sehat Sahulat interact with Trikafta? The Sehat Sahulat Program's Rs. 1,000,000 per family per year ceiling does not stretch to cover a year of Trikafta therapy at US WAC, and the program is generally structured around in-network empaneled hospital treatment rather than imported drug procurement. Patients who qualify for Sehat Sahulat can still use it for hospitalisation, supportive care, and procedures while Trikafta is procured separately on a cash-pay basis.

What if my child is under 2 years old? Trikafta is approved for patients aged 2 years and older. Reserve Meds will not coordinate intake for a patient outside the FDA-approved age range. We will route the family to local CF-center care planning until the patient reaches eligibility.

What about Alyftrek? Alyftrek (vanzacaftor, tezacaftor, deutivacaftor) is Vertex's once-daily successor approved by the FDA in December 2024. For Pakistani families the Alyftrek discussion is typically a clinician-driven choice about continuity, real-world experience, and acquisition cost. Trikafta carries longer real-world data and a broader international footprint. The switch decision belongs to your CF physician.

What is the safety profile? Most common adverse events on the pivotal trials (VX17-445-102 and VX17-445-103) were headache, upper respiratory infection, abdominal pain, rash, and elevated transaminases. Drug-induced liver injury, cataracts in pediatric patients, and hypersensitivity reactions are labeled warnings. Baseline and periodic liver function testing and pediatric ophthalmologic examination are part of the monitoring plan.

Can the medicine be delivered to our home? The dispensing facility must be a Pakistan-licensed pharmacy. For Trikafta the medicine moves into a hospital outpatient pharmacy or a specialised licensed import pharmacy, and the family collects it from there. Direct-to-home delivery without a licensed dispensing facility in the chain is not the model.

Where Reserve Meds fits in Trikafta cases

Reserve Meds is a US-based concierge coordinator. We do not replace your CF physician, do not replace DRAP, and do not replace the dispensing hospital pharmacy or in-country importer. For Trikafta specifically we orchestrate the US-side sourcing through the Vertex specialty-pharmacy network, the regulatory documentation kit your physician needs (genotype letter template, dosing reference by weight band, monitoring plan summary, DRAP pharmacovigilance reference), international ambient-controlled logistics under chain-of-custody, and a single named coordinator who carries the family from intake through delivery and reorders. F508del genotype documentation, CF-center referral letter, and current weight-band confirmation are mandatory intake artefacts. We do not coordinate off-label use, and we will decline intake for patients without at least one F508del allele or another labeled CFTR-responsive variant.

Next step

If your CF physician has decided Trikafta is the right next step and DRAP Special Permission is the route, join the waitlist below and we will confirm eligibility within 24 to 48 hours and send the documentation kit to your physician and to the dispensing hospital pharmacy.

Join the Trikafta waitlist

Reserved for you.